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Abstract
Vesicular stomatitis virus (VSV) expressing the Ebola virus (EBOV) glycoprotein (GP) in place of the VSV glycoprotein G (VSV/
EBOV-GP) is a promising EBOV vaccine candidate which has already entered clinical phase 3 studies. Although this chimeric
virus was tolerated overall by volunteers, it still caused viremia and adverse effects such as fever and arthritis, suggesting
that it might not be sufficiently attenuated. In this study, the VSV/EBOV-GP vector was further modified in order to achieve
attenuation while maintaining immunogenicity. All recombinant VSV constructs were propagated on VSV G protein
expressing helper cells and used to immunize guinea pigs via the intramuscular route. The humoral immune response was
analysed by EBOV-GP-specific fluorescence-linked immunosorbent assay, plaque reduction neutralization test and in vitro
virus-spreading inhibition test that employed recombinant VSV/EBOV-GP expressing either green fluorescent protein or
secreted Nano luciferase. Most modified vector constructs induced lower levels of protective antibodies than the parental
VSV/EBOV-GP or a recombinant modified vaccinia virus Ankara vector encoding full-length EBOV-GP. However, the VSV/
EBOV-GP(F88A) mutant was at least as immunogenic as the parental vaccine virus although it was highly propagation-
restricted. This finding suggests that VSV-vectored vaccines need not be propagation-competent to induce a robust humoral
immune response. However, VSV/EBOV-GP(F88A) rapidly reverted to a fully propagation-competent virus indicating that a
single-point mutation is not sufficient to maintain the propagation-restricted phenotype.
INTRODUCTION
Since the first isolation of Marburg virus in 1967, several
other filoviruses have been discovered. The family of Filovir-
idae presently comprises the genus Marburgvirus with the
species Marburg virus (MARV) and Ravn virus (RAVV),
the genus Ebolavirus containing the species Zaire ebolavirus
(EBOV), Sudan ebolavirus (SUDV), Bundibugyo ebolavirus
(BDBV), Reston ebolavirus (RESTV), and Taï Forest ebolavi-
rus (TAFV), and the genus Cuevavirus with the species
Lloviu virus (LLOV). Several filoviruses cause severe hae-
morrhagic fever diseases in humans and non-human pri-
mates with the highest mortality rates associated with Zaire
ebolavirus. The first EBOV outbreak was noted in 1976 in
the Democratic Republic of Congo (former Zaire). Since
then several small sporadic outbreaks with a limited number
of persons affected have occurred [1]. An unusually large
outbreak took place in 2014 in West Africa and caused at
least 28 637 cases of Ebola virus disease (EVD), claiming
11 315 deaths [2, 3]. This outbreak has greatly pushed the
search for vaccines and antivirals which would protect from
this fatal disease. However, all these efforts were compli-
cated by the absolute necessity to handle EBOV and other
filoviruses in laboratories strictly complying with biosafety
level 4.
A recombinant vesicular stomatitis virus (VSV) expressing
the EBOV glycoprotein (EBOV-GP) in place of the VSV
glycoprotein (VSV-G) was one of the first Ebola vaccine
candidates showing promising results. This live-attenuated
recombinant vector vaccine induced a protective immune
response in non-human primates [4] and mediated protec-
tion even if applied post exposure to EBOV [5]. There is
strong evidence that protection was mediated by antibodies
directed to the EBOV glycoprotein [6]. As wild-type VSV is
characterized by a pronounced neurotropism in rodent ani-
mal models [7, 8], concerns over the safety of the chimeric
VSV/EBOV-GP vaccine were raised. However, the chimeric
virus was demonstrated to completely lack neurovirulence
in non-human primates [9] and was even tolerated by
immunocompromised animals [10]. Following the EBOV
outbreak in West Africa in 2014 clinical phase I/II studies
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were launched in order to validate the recombinant VSV
vector vaccine in human volunteers. The vaccine seemed to
induce a protective immune response [11]. However,
adverse effects such as fever and long-lasting arthritis were
observed in some volunteers [12, 13], suggesting that the
VSV vector might not be sufficiently attenuated.
Since expression of EBOV-GP in place of VSV-G was found
to attenuate the VSV vector to a significant degree, no addi-
tional mutations have been introduced into the vector back-
bone. In this study, we aimed at further modifying the VSV
vector backbone or the EBOV-GP antigen in order to pro-
duce a more attenuated but still immunogenic vaccine. The
humoral immune response to these experimental vaccines
was studied in the guinea pig model by employing EBOV-
GP-specific fluorescence-linked immunosorbent assay
(FLISA), plaque reduction neutralization test (PRNT) and a
novel virus-spreading inhibition test taking advantage of
recombinant VSV/EBOV-GP reporter virus-encoding
secreted Nano luciferase (sNLuc). The attenuated vector
vaccines were compared with the unmodified VSV*DG
(EBOV-GP) vaccine and with recombinant modified vac-
cinia virus Ankara (MVA) vectors expressing the same
EBOV-GP antigen.
RESULTS
Generation of modified VSV-EBOV vaccine vectors
The EBOV vaccine candidate which has already entered
clinical phase 3 studies represents a chimeric VSV in which
the envelope glycoprotein (G) gene has been replaced by the
EBOV (species Zaire) glycoprotein (GP) gene [14]. We gen-
erated a very similar virus, VSV*DG(EBOV-GP), which dif-
fered from VSV/EBOV-GP in additionally encoding a
reporter protein, either green fluorescent protein (GFP) or
sNLuc (Fig. 1a). The EBOV-GP contains a heavily O-glyco-
sylated mucin-like domain which may have an impact on
the immunogenicity and cytotoxicity of the protein [15, 16].
To analyse the role of this domain in VSV vector-driven
immune responses, recombinant VSV with a modified
EBOV-GP lacking the mucin-like domain (VSV*DG
(EBOV-GP
Dmuc) was generated (Fig. 1b). In addition, the
recombinant vector vaccine VSVDG(EBOV-GP,VP40)
encoding both EBOV-GP and EBOV-VP40 was produced
(Fig. 1a), as previous results suggested a positive impact of
the EBOV matrix protein VP40 on vaccine efficacy [17].
Two strategies were pursued to make the VSV vector safer –
modification of the vector backbone and modification of the
EBOV-GP antigen. The vector backbone was modified by
introducing four mutations into the matrix (M) protein
gene (Mq) that are known to abolish the host shut-off activ-
ity of the protein [18]. We anticipated that the resulting
vector, VSV*MqDG(EBOV-GP) (Fig. 1a), would be unable
to block the synthesis and release of type I IFN, which
would interfere with the dissemination of the viral vector.
The EBOV-GP antigen was modified in order to produce a
propagation-incompetent VSV-vectored vaccine. We
hypothesized that a EBOV-GP lacking the transmembrane
domain would not be incorporated into the VSV envelope
and thus could not substitute for the deleted VSV-G pro-
tein. Therefore, a soluble version of EBOV-GP, consisting of
the GP ectodomain and a carboxyterminal GCN4-pII trime-
rization domain (Fig. 1b), was expressed from the VSV*DG
(EBOV-sGP3) genome. In addition, VSV*DG(EBOV-
sGP3
Dmuc) was constructed which encoded a secreted tri-
meric version of the glycoprotein without the mucin-like
domain (Fig. 1b). As an alternative approach, full-length
but functionally impaired EBOV-GP with point mutations
F88A or P537R were expressed from the VSVDG genome.
The mutation F88A has previously been shown to render
the glycoprotein defective for entry into a variety of human
cell types [19, 20]. The mutation P537R is located in the
putative fusion domain and was demonstrated to interfere
with the membrane fusion activity of EBOV-GP [21, 22].
Analysis of recombinant VSV vector replication
in vitro
Multi-step replication of the generated recombinant VSV
vectors was analysed on Vero cells using a m.o.i. of 0.0001
focus-forming units (ffu) cell 1 (Fig. 2a). The reference virus
VSV*DG(EBOV-GP) (red curve) reached infectious titres of
2.7107 ffuml 1 at 48 h post infection (p.i.) while the
parental virus VSV* encoding the homotypic G protein
Fig. 1. Genome maps of recombinant VSV vectors. (a) The original
VSV contains five transcription units encoding the nucleoprotein N, the
phosphoprotein P, the matrix protein M, the glycoprotein G and the
large RNA-dependent RNA polymerase L. The VSV vector was modi-
fied by replacing the G gene with the EBOV-GP gene (either authentic
or modified) and by inserting an additional transcription unit encoding
either GFP, sNLuc or EBOV-VP40. Mq denotes a modified M gene
encoding a mutant M protein which is characterized by the amino acid
changes M33A, M51R, V221F and S226R. (b) Protein maps of authentic
and modified EBOV-GP, indicating the location of the signal peptide
(SP), receptor-binding domain (RBD), glycan cap, mucin-like domain
(mucin), fusion loop (FL), heptad repeat (HR) region and transmem-
brane (TM) domain. The furin cleavage site (red line), the cleavage
products GP1 and GP2, and the amino acid positions F88 and P537
are indicated as well.
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replicated faster and produced significantly higher titres at
all times of the kinetics (light blue curve). A maximum
infectious titre of 5108 ffuml 1 was reached by VSV* at
36 h p.i. These findings confirmed the previous notion that
recombinant VSV encoding the EBOV-GP in place of the
VSV-G envelope protein is attenuated compared to wild-
type VSV, although it is still able to produce significantly
high infectious titres in cell culture [14]. The replication
kinetics of the modified vector VSV*MqDG(EBOV-GP)
encoding the mutant matrix protein Mq (grey curve) did
not reveal significant differences when compared with the
VSV*DG(EBOV-GP) kinetics. Similarly, the corresponding
parental virus VSV*Mq encoding the homotypic VSV-G
glycoprotein showed a very similar (not statistically differ-
ent) kinetics as VSV*, indicating that the Mq protein did
not negatively affect viral replication in this cell line. Com-
pared to the reference virus VSV*DG(EBOV-GP), VSV*DG
(EBOV-GP
Dmuc), which lacked the mucin-like domain of
EBOV-GP, produced significantly higher titres at 24 and
36 h p.i. (yellow curve). In contrast, VSVDG(EBOV-GP,
VP40) was significantly attenuated compared to VSV*DG
(EBOV-GP) and reached only 3.6106 ffuml 1 at 48 h p.i.
(brown curve). As expected, the recombinant viruses encod-
ing soluble EBOV-GP, VSV*DG(EBOV-sGP3) and
VSV*DG(EBOV-sGP3
Dmuc), were not able to propagate on
Vero cells (Fig. 2a). Similarly, chimeric VSV containing full-
length GP with either the mutation F88A or P537R did not
produce significant levels of infectious virus following infec-
tion at low dose (m.o.i. of 0.0001 ffu cell 1). However, all
viruses unable to replicate autonomously on Vero cells
could be propagated to high titres (about 108 ffu ml 1) on
BHK-G43 helper cells expressing the VSV-G protein in a
regulated manner (Fig. 2b). Using an m.o.i. of 0.1 ffu cell 1,
VSV*DG(EBOV-GPF88A) and VSV*DG(EBOV-GPP537R)
produced low infectious virus titres on non-induced BHK-
G43 helper cells (about 102 and 103 ffu ml 1, respectively).
Compared to the reference virus VSV*DG(EBOV-GP),
propagation of VSV*DG(EBOV-GPF88A) and VSV*DG
(EBOV-GPP537R) was significantly restricted on other cell
lines (Fig. 2c). However, VSV*DG(EBOV-GPP537R) turned
out to be less restricted than VSV*DG(EBOV-GPF88A) on
most cell lines with the exception of HeLa cells. In particu-
lar, Huh7 cells allowed VSV*DG(EBOV-GPP537R) to repli-
cate to titres that were only 1 log10 lower than those
produced by the parental virus VSV*DG(EBOV-GP). In
order to elucidate the stability of the attenuated phenotypes,
VSV*DG(EBOV-GPF88A) and VSV*DG(EBOV-GPP537R)
Fig. 2. Propagation competence of recombinant VSV vectors. (a) Multi-
cycle replication of recombinant VSV. Vero cells grown in six-well plates
were infected with the indicated recombinant viruses using an m.o.i. of
0.0001 ffu cell 1. At the indicated times, aliquots of the cell-culture
supernatant were collected and infectious virus titrated on Vero cells.
Mean values and SD of three independent experiments are shown.
Asterisks indicate significantly different infectious virus titres when
compared to VSV*DG(EBOV-GP). (b) Virus yield on helper cells. BHK-G43
cells in 24-well plates were treated with mifepristone to induce VSV-G
protein expression (dark grey bars) or were left untreated (light grey
bars). Cells were infected with the indicated viruses using an m.o.i. of
0.1 ffu cell 1 and maintained for 24 h in medium with or without mifep-
ristone. Medium without mifepristone was supplemented with a neu-
tralizing antibody directed to the VSV-G protein in order to inactivate
any remaining input virus. Infectious virus released into the cell-culture
medium was titrated on Vero cells. Results are shown as the mean plus
SD of three independent experiments. Asterisks indicate significantly dif-
ferent infectious virus titres when compared to VSV*DG(EBOV-GP). (c)
Propagation of GP mutant VSV on mammalian cell lines. The indicated
cell lines were infected with VSV*DG(EBOV-GPF88A) (blue bars), VSV*DG
(EBOV-GPP537R) (orange bars) and parental VSV*DG(EBOV-GP) (gey
bars) using an m.o.i. of 0.1 ffu cell 1 and incubated for 24 h in the pres-
ence of neutralizing antibody directed to the VSV-G protein. Infectious
virus titres released into the cell-culture supernatant were determined.
Mean titres and SD of three infection experiments are shown. Black
asterisks indicate significantly different infectious virus titres when
compared to VSV*DG(EBOV-GP). Red asterisks indicate significantly dif-
ferent virus titres when comparing VSV*DG(EBOV-GPF88A) with VSV*DG
(EBOV-GPP537R).
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were serially passaged on BHK-21 cells, each virus in six
replicates (Fig. 3a). After a few passages, viruses producing
significantly higher titres than the original viruses emerged
in several replicates. Sequence analysis of the GP cDNA
derived from two selected passage 5 viruses revealed three
mutations in the GPF88A gene, A88V, R164G and P421L,
and two mutations in the GPP537R gene, Y261F and R537Q
(Fig. 3b), indicating that the propagation-restricted viruses
VSV*DG(EBOV-GPF88A) and VSV*DG(EBOV-GPP537R)
are not genetically stable.
In order to investigate the induction of type I IFN or other
antiviral cytokines by the vaccine candidates, normal
human dermal fibroblasts (NHDF) were infected with the
recombinant viruses using an m.o.i. of 1 ffu cell 1. At
24 h p.i., cell-culture supernatants were collected and heated
for 30min at 55

C to inactivate any infectious virus [23].
The cell-culture supernatants were serially diluted and sub-
sequently incubated with HeLa cells for 24 h. Finally, the
induction of an antiviral state in the HeLa cells was deter-
mined with a bioassay taking advantage of VSV*DG(Luc)
replicon particles encoding the firefly luciferase reporter
protein [24]. It turned out that all viruses that expressed
wild-type M protein completely suppressed the synthesis of
antiviral cytokines, whereas the infection of NHDF with
VSV*Mq or VSV*MqDG(EBOV-GP) led to a strong induc-
tion of type I IFN (Fig. 4a). Accordingly, the dissemination
of VSV*MqDG(EBOV-GP) was severely restricted in
NHDF but was not affected in Vero cells that are unable to
produce type I IFN (Fig. 4b). In contrast, VSV*DG(EBOV-
GP) expressing wild-type VSV-M protein showed spreading
in both NHDF and Vero cells, although dissemination was
much slower in NHDF compared to Vero cells. The replica-
tion of M protein-modified VSV was also studied using
sNLuc reporter viruses. Following infection of NHDF with
VSVMqDG(EBOV-GP,sNLuc) using an m.o.i. of 0.001 ffu
cell 1, sNLuc expression levels were suppressed approxi-
mately 100-fold compared to cells infected with VSVDG
(EBOV-GP,sNLuc) (Fig. 4c). However, attenuation of
VSVMqDG(EBOV-GP,sNLuc) was compensated if the cells
were infected with a higher virus dose. Using an m.o.i. of 0.1
ffu cell 1, the luciferase reporter reached levels at 36 and
48 h p.i. that were similarly high as those produced by a
100-fold lower dose of VSVDG(EBOV-GP,sNLuc).
Analysis of vector-driven EBOV-GP expression
For detection of mature EBOV-GP at the cell surface, VSV
vector-infected cells were labelled with sulfo-NHS-LC-LC-
biotin. The biotinylated cell surface proteins were precipi-
tated from cell lysates with immobilized streptavidin,
Fig. 3. Reversion of the growth-restricted phenotype of VSV*DG(EBOV-GPF88A) and VSV*DG(EBOV-GPP537R). (a) The indicated viruses
were serially passaged on BHK-21 cells (replicates R1 to R6) and infectious virus titres (24 h p.i.) determined for passage 2 (white
bars), passage 3 (light grey bars), passage 4 (dark grey bars) and passage 5 (black bars). Passage 5 viruses that were used to deter-
mine the cDNA sequence of GP are indicated by red arrows. (b) The complete primary sequence of GP from passaged viruses was
determined but only regions containing amino acid changes are depicted. The same mutations were found in the second replicate of
VSV*DG(EBOV-GPF88A) and VSV*DG(EBOV-GPP537R), respectively.
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separated by SDS-PAGE under reducing conditions and
analysed by Western blot using guinea pig anti-EBOV-GP
serum. At 14 h p.i. of Vero cells with either VSV*DG
(EBOV-GP) or VSV*MqDG(EBOV-GP), GP migrating as a
single band of 120 kDa was detected at the cell surface
(Fig. 5a). In contrast, EBOV-GP
Dmuc lacking the heavily
O-glycosylated mucin-like domain showed a drastically
reduced apparent molecular weight of about 55 kDa. Infec-
tion of cells with VSVDG(EBOV-GP,VP40) resulted in very
low EBOV-GP expression levels at the cell surface at
14 h p.i., whereas EBOV-GPF88A and EBOV-GPP537R were
well expressed. As expected, the soluble EBOV
glycoproteins secGP3 and secGP3Dmuc were not found at
the cell surface. The EBOV matrix protein VP40 was exclu-
sively detected in lysates of cells that had been infected with
VSVDG(EBOV-GP,VP40).
Cell surface expression of recombinant EBOV-GP was
also analysed by flow cytometry using mouse polyclonal
anti-EBOV-GP serum. Using this approach, the mutant gly-
coproteins EBOV-GPF88A and EBOV-GPP537R and, in par-
ticular, EBOV-GP
Dmuc were detected at the cell surface at
higher levels than the wild-type glycoprotein (Fig. 5b, left
panel). The anti-EBOV mouse serum also reacted weakly
with Vero cells infected with VSV*DG(secGP3) and
Fig. 4. Induction of type I IFN synthesis in VSV vector-infected cells. (a) Release of type I IFN by infected cells. NHDF were infected
with the indicated viruses (m.o.i. of 10). At 24 h p.i., cell-culture supernatants were sampled and heated for 30min at 55

C to inactivate
infectious virus. The antiviral activity released into the cell-culture medium was titrated on HeLa cells using a previously described
VSV replicon-based bioassay [24]. The antiviral activity was expressed as inhibitory concentration 50% (IC50). Mean values and SD of
three infection experiments are shown. The broken line indicates the lower limit of detection. Asterisks indicate secretion of type I IFN
at levels that are significantly different (P<0.05) from the mock control. (b) Spreading of chimeric VSV in cell culture. NHDF and Vero
cells were infected with either VSV*DG(EBOV-GP) or VSV*MqDG(EBOV-GP) using an m.o.i. of 0.0001 ffu cell 1. Spreading of virus in the
cell monolayer was monitored by detection of GFP fluorescence with an inverted fluorescence microscope. The bar represents
200µm. (c) Multi-cycle replication of sNLuc reporter viruses in IFN-competent cells. NHDF were infected with either VSVDG(EBOV-GP,
sNLuc) (red line) or VSVMqDG(EBOV-GP,sNLuc) (black lines) using an m.o.i. of either 0.001 ffu cell 1 (circles), 0.01 ffu cell 1 (rhombs)
or 0.1 ffu cell 1 (squares). sNLuc activity was determined in the cell-culture medium at the indicated times. Mean luciferase values
and SD of three infection experiments are shown. Asterisks indicate significant different luciferase values compared to VSVDG(EBOV-
GP,sNLuc).
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VSV*DG(secGP3
Dmuc). This signal might be due to secreted
EBOV-GP which stayed associated with the cell surface. A
clear signal was detected for secGP3 and secGP3
Dmuc by
intracellular staining assay (Fig. 5b, right panel), confirming
that both secGP3 and secGP3
Dmuc were actually expressed
by the infected cells.
Analysis of immune sera from vaccinated guinea
pigs
Guinea pigs were immunized via the intramuscular route
with the recombinant vector vaccines (108 ffu per animal),
which had been produced on helper cells providing the
VSV-G protein in trans, and blood was collected 4weeks
Fig. 5. Recombinant VSV-driven expression of EBOV-GP. Vero cells in 12-well plates were infected with the indicated viruses using an
m.o.i. of 10 ffu cell 1. (a) At 14 h p.i., cell surface proteins were labelled with biotin, precipitated from cell lysates by immobilized strep-
tavidin, and analysed by Western blot using either guinea pig polyclonal anti-EBOV-GP serum or rabbit anti-VP40 serum. The positions
of proteins with defined molecular weight are indicated on the left-hand side. (b) Flow cytometric analysis of EBOV-GP expression.
Infected Vero cells were incubated with a LIVE/DEAD fixable violet dead cell marker. Subsequently, cells were stained either directly
for EBOV-GP cell surface expression (left panel) or fixed and permeabilized to allow detection of intracellular EBOV-GP (right panel).
EBOV-GP was detected using a mouse polyclonal anti-EBOV-GP anti-serum and anti-mouse IgG-allophycocyanin. Expression levels of
EBOV-GP are represented in histogram plots of live, GFP-positive, i.e. infected cells.
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after the primary immunization. Subsequently, the animals
were immunized a second time with the same vector and
dose, and sera were prepared 4weeks later. The immune
sera were titrated by taking advantage of a FLISA that was
based on MVA-BN-EBOV-GP-infected Vero cells (Fig. 6a).
Four weeks after the primary immunization with our refer-
ence vaccine VSV*DG(EBOV-GP), immune serum revealed
an EBOV-GP-specific antibody titre of 800 (a dilution of
1 : 800 was still able to discriminate between MVA-BN-
EBOV-GP infected and non-infected cells). Four weeks after
the second immunization, the antibody titre had increased,
but this increase was rather small and could not be tested as
significantly different. Likewise, small and non-significant
increases of antibody titres were found following the second
immunization with VSV*DG(EBOV-GP
Dmuc), VSVDG
(EBOV-GP,VP40), VSV*DG(EBOV-sGP3) and VSV*DG
(EBOV-sGP3
Dmuc), whereas a significant boosting effect
was observed with VSV*MqDG(EBOV-GP), VSV*DG
(EBOV-GPF88A) and VSV*DG(EBOV-GPP537). The first
immunization with VSVDG(EBOV-GP,VP40) and
VSV*DG(EBOV-GPP537) led to antibody titres that were as
high as those induced by the reference vaccine, while
VSV*DG(EBOV-GPF88A) induced significantly higher titres.
In contrast, following the first immunization with
VSV*MqDG(EBOV-GP) and VSV*DG(EBOV-GP
Dmuc)
antibody titres were significantly lower than those induced
by the reference vaccine, while vaccination with soluble
antigen (secGP3 or secGP3
Dmuc) did not result in detectable
antibody titres. Following the second immunization with
VSVDG(EBOV-GP,VP40) or VSV*DG(EBOV-GPF88A),
antibody titres were as high as those induced by the refer-
ence vaccine (second immunization), while VSV*DG
(EBOV-GPP537) induced a significantly higher titre. In con-
trast, the antibody titres induced by the second application
of VSV*MqDG(EBOV-GP) or VSV*DG(EBOV-GP
Dmuc)
were significantly lower than those induced by VSV*DG
(EBOV-GP). These findings suggest that VSV*MqDG
(EBOV-GP) and VSV*DG(EBOV-GP
Dmuc) are less immu-
nogenic than the reference virus VSV*DG(EBOV-GP). The
vaccine constructs VSV*DG(EBOV-sGP3) and VSV*DG
(EBOV-sGP3
Dmuc) seemed to be nonimmunogenic, at least
with regard to the induction of antibodies that would bind
to native EBOV-GP antigen.
In order to functionally characterize guinea pig immune
sera, a PRNT was performed with VSV*DG(EBOV-GP) as a
surrogate virus. This assay was chosen because recent work
suggested a high degree of correlation between BSL-2 pseu-
dotyped VSV fluorescence reduction neutralization test and
BSL-4 EBOV neutralization assays [25]. We used an 80%
PRNT (PRNT80), as the sensitivity of the test was not suffi-
ciently high to capture the 90% reduction values for the pri-
mary immunization sera. The immune sera from the
vaccine groups VSV*DG(EBOV-GP), VSV*MqDG(EBOV-
GP), VSV*DG(EBOV-GP
Dmuc), VSV*DG(EBOV-GPF88A,
VSV*DG(EBOV-sGP3) and VSV*DG(EBOV-sGP3
Dmuc)
revealed PRNT80titres (Fig. 6b), which followed a very simi-
lar pattern as seen before with FLISA (Fig. 6a). However,
animals immunized with either VSV*DG(EBOV-GPP537) or
VSVDG(EBOV-GP,VP40) produced significantly lower
PRNT80 titres than animals that had received the reference
vaccine. Since all three vaccines induced similar antigen-
binding antibody titres (Fig. 6a), the quality of the antibod-
ies induced by the different vaccine constructs likely
differed. In contrast to FLISA, all vaccine constructs except
VSV*DG(EBOV-GP
Dmuc) revealed significantly increased
PRNT80 titres after the second immunization, indicating
that the quality of the neutralizing antibodies was benefiting
from the second immunization while having only a moder-
ate effect on antigen-binding antibody levels. We also ana-
lysed immune sera from guinea pigs that had been
immunized with recombinant MVA [26], a viral vector
which is propagation-incompetent in most mammalian cells
[27, 28]. Four weeks after the primary immunization with a
high dose (5108 ffu) of either MVA-BN-EBOV-GP
(expressing EBOV-GP) or MVA-BN-EBOV-VLP (express-
ing EBOV-GP, EBOV-VP40 and TAFV-NP), PRNT80 titres
were not detectable or very low (Fig. 6b). Only after the sec-
ond immunization, antibody titres increased significantly
reaching mean values of 188 and 68, respectively.
Since antibodies may not only interfere with receptor-bind-
ing and fusion but also with virus-budding and release [29],
we wondered whether a virus-spreading inhibition test
might be more sensitive than the PRNT80 test. To test this
hypothesis, Vero cells were infected with VSV*DG(EBOV-
GP,sNLuc), a chimeric VSV expressing the sNLuc reporter
protein, using an m.o.i. of 0.001 ffu cell 1, and subsequently
incubated with medium containing guinea pig anti-EBOV-
GP immune serum. At 24 h p.i., sNLuc activity in the cell-
culture supernatant was determined and results expressed
as the inhibitory concentration suppressing the spreading of
VSV*DG(EBOV-GP,sNLuc) by 90% (IC90) (Fig. 6c). It
turned out that the IC90titres for most vaccine groups
showed a similar pattern as the PRNT80 titres although the
absolute values were generally higher. In contrast to PRNT,
however, immune sera from animals immunized once with
VSVDG(EBOV-GP,VP40) revealed inhibitory antibody
titres that were as high as those induced by the reference
vaccine. There were also other discrepancies observed when
the relative PRNT80 and IC90 titres were compared.
Immune sera that were prepared following the second
immunization with VSV*DG(EBOV-GPP537) showed IC90
titres that were as high as those induced by the reference
vaccine, although PRNT80 titres were significantly different
between the two vaccine groups. Furthermore, a single
immunization with either MVA-BN-EBOV-GP or MVA-
BN-EBOV-VLP induced similar IC90 titres as VSV*DG
(EBOV-GP), although the corresponding PRNT80 titres
were low or undetectable (Fig. 6b). These discrepancies
between PRNT80 and IC90 titres might be at least partially
attributed to the higher sensitivity of the virus-spreading
inhibition test. It should also be noted that the virus-spread-
ing inhibition test would also gather EBOV-GP-specific
antibodies that interfere with virus-budding and release.
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Fig. 6. Analysis of the antibody responses of guinea pigs vaccinated with recombinant VSV. (a) FLISA. Vero cells were grown in 96-
well plates and infected with MVA-BN-EBOV-GP (m.o.i. of 0.05 ffu cell 1). At 24 h p.i., the cells were fixed with paraformaldehyde and
incubated with serially diluted serum pools from vaccinated guinea pigs (four to five animals per vaccine group) and subsequently
with Alexa 488-conjugated anti-guinea pig IgG serum. FLISA antibody titres were calculated by determining the reciprocal value of the
highest immune serum dilution allowing discrimination of infected from non-infected Vero cells by indirect immunofluorescence. Mean
values and SD of three independently performed titrations are shown. (b) Analysis of guinea pig sera by PRNT. Serially diluted serum
from vaccinated guinea pigs (n=4 to 5 animals per vaccine group) were incubated for 60min with 100 ffu of VSV*DG(EBOV-GP). Vero
cell monolayers grown in 96-well cell-culture plates were inoculated with the virus/antibody mixture for 1 h and then replaced by
200µl of medium containing 0.8% methyl cellulose. Following an incubation period of 24 h, the GFP-positive cell foci were counted
under an inverted fluorescence microscope. The reciprocal serum dilution causing a reduction of plaque numbers by 80% (PRNT80)
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DISCUSSION
The generation of live-attenuated virus vaccines has always
been a great challenge irrespective of whether these vaccines
have been generated by recombinant DNA technologies or
by classical means (e.g. serial passaging the virus on differ-
ent host cell lines). As attenuation of viruses is frequently
accompanied with loss in immunogenicity, a major diffi-
culty in generating live-attenuated virus vaccines is to find
an adequate balance between sufficient attenuation (safety)
and maintenance of immunogenicity. The recently devel-
oped Ebola vaccine candidate VSV/EBOV-GP is a modified
VSV in which the VSV-G gene has been replaced by the
EBOV glycoprotein gene [14]. VSV/EBOV-GP turned out
to be highly attenuated as intracerebral inoculation of non-
human primates with this virus did not result in apparent
disease [9, 10]. It was therefore surprising to see that the
vaccine caused adverse effects such as fever and arthritis in
human volunteers who were enrolled in a clinical phase 2
study in Geneva, Switzerland [11–13]. These unwanted
complications might be related to the ability of the chimeric
virus to still cause viremia in humans [30], a feature which
has also been observed in non-human primates [4]. The
aim of our study was therefore to develop a highly attenu-
ated VSV-based vector vaccine with a compromised ability
of spreading.
Our first approach of attenuation was based on a VSV vec-
tor encoding a modified VSV-M protein (Mq), which is
known to be free of host shut-off activity [18]. As expected,
infection of NHDF with VSV*MqDG(EBOV-GP) led to the
synthesis and secretion of type I IFN. Due to the paracrine
action of this antiviral cytokine, the virus was unable to
spread in cell culture beyond the primary infected cells. In
addition, the autocrine action of type I IFN resulted in sup-
pression of virus replication and lower reporter protein lev-
els (see Fig. 4). The lower antigen levels and reduced
spreading in tissues might explain why immunization with
this vaccine induced lower levels of neutralizing antibodies
compared to a vaccine vector which expressed the wild-type
M protein. However, when VSV*MqDG-EBOV-GP was
applied a second time, antibody titres were significantly
boosted. In line with this observation, others have shown
that VSV-vectored vaccines that express a modified M pro-
tein are sufficiently immunogenic [31] and can protect ani-
mals from infection with vaccinia virus or VSV [32, 33].
Future experiments will show whether VSV*MqDG(EBOV-
GP) is able to protect non-human primates from EBOV
challenge infection. As Mq-modified VSV is restricted in
spreading and probably unable to cause viremia, it repre-
sents a safer vector vaccine than the unmodified VSV vec-
tor. Of note, Mq-modified VSV vectors can be propagated
to high titres on Vero cells which have a defect in the syn-
thesis of type I IFN.
Another strategy of attenuation was based on a modified
EBOV-GP antigen in which the large mucin-like domain
had been deleted. This modification did not affect propaga-
tion of VSV*DG(EBOV-GP
Dmuc) on Vero cells, indicating
that this domain is not essential for viral replication in vitro.
VSV*DG(EBOV-GP
Dmuc) replicated even faster than
VSV*DG-EBOV-GP, a phenomenon that may be attributed
to the shorter genome of VSV*DG(EBOV-GP
Dmuc) differing
from the parental VSV*DG(EBOV-GP) genome by 570
nucleotides. Although the modified antigen was expressed
at the cell surface at high levels, it induced significantly less
neutralizing antibodies in vaccinated guinea pigs than the
authentic EBOV-GP antigen, indicating that the deletion of
the mucin-like domain had a negative impact on the immu-
nogenic properties of the viral glycoprotein. Indeed, a num-
ber of known protective antibodies such as 6D8, 13F6 and
13C6 have been shown to bind to the mucin-like domain
[34, 35].
VSVDG(EBOV-GP,VP40) expressing both EBOV-GP and
EBOV-VP40 turned out to be significantly attenuated on
Vero cells, showing slower replication kinetics and reaching
lower final virus titres than the reference vaccine VSV*DG
(EBOV-GP). Correspondingly, EBOV-GP expression levels
at the cell surface were also quite low early in infection. Nev-
ertheless, immunization of guinea pigs with VSVDG
(EBOV-GP,VP40) resulted in antigen-binding antibody
titres that were comparable to those induced by VSV*DG
(EBOV-GP). However, neutralizing activity of these anti-
bodies was significantly lower than those induced by
VSV*DG(EBOV-GP). This attenuation has not been
observed with the MVA-BN-EBOV-VLP vector expressing
the same two EBOV antigens [26]. It is therefore possible
that the VP40 protein had a specific negative impact on
VSV replication/transcription or VSV matrix protein-medi-
ated budding. However, work with a similar VSV vaccine
construct based on SUDV-GP and SUDV-VP40 suggested
that antibody titres stimulated by a homologous prime/
boost regimen might be sufficiently high to provide protec-
tion of non-human primates [17].
was calculated. Mean titres and SD were calculated for the immune sera collected from four to five individual guinea pigs per group.
(c) Inhibition of virus spreading in vitro. Vero cells were infected with VSV*DG(EBOV-GP,sNLuc) using an m.o.i. of 0.005 ffu cell 1 and
maintained in medium containing serial dilutions of immune sera which were collected 4weeks after the first and 4weeks after the
second immunization of guinea pigs with recombinant VSV expressing the indicated antigens. At 24 h p.i., sNLuc activity in the cell-cul-
ture supernatant was determined. The reciprocal serum dilution leading to 90% inhibition of reporter activity (IC90) was determined
(relative to virus-spreading experiments in the presence of naïve guinea pig serum). Mean IC90 titres and SD were calculated for
immune sera that were collected from four to five individual guinea pigs per vaccine group. (a–c) Black asterisks indicate significantly
different titres (P<0.05) with respect to the reference vaccine VSV*DG(EBOV-GP). Red asterisks indicate significantly different antibody
titres when comparing first and second immunization.
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There is evidence that adenovirus-vectored and MVA-vec-
tored Ebola vaccines can induce protective immune
responses in human volunteers even though these vectors
are propagation-incompetent [36]. This observation stimu-
lated us to generate a propagation-incompetent VSV-vec-
tored EBOV vaccine by expressing soluble versions of the
EBOV-GP protein. As these glycoproteins lacked the trans-
membrane domain, they could not take part in the process
of virus budding. These vector vaccines were propagated to
high titres on helper cells that expressed the VSV-G protein
in a regulated manner [37]. Nevertheless, immunization of
guinea pigs with these vaccines resulted in only low titres of
neutralizing antibodies. Indeed, the multivalent interaction
of cognate B cell receptors with multiple GP spikes pre-
sented on the viral envelope or the surface of GP-expressing
cells may particularly be important to induce conformation-
dependent neutralizing antibodies. This hypothesis is sup-
ported by the observation that secreted GP, which is
produced at large amounts by EBOV-infected cells as a
result of RNA editing [38, 39], induces only low levels of
neutralizing antibodies but serves as a decoy antigen which
snatches neutralizing antibodies away [40, 41].
As an alternative approach for the generation of propaga-
tion-restricted VSV-vectored Ebola vaccine, we expressed
mutant EBOV-GP known to be functionally defective. The
F88A mutation has been reported to render EBOV-GP
defective for mediating virus entry into a variety of human
cell types, including antigen-presenting cells [19]. The
P537R mutation, which is located close to the putative
fusion domain of the glycoprotein, was shown to compro-
mise virus entry although it did not affect EBOV-GP trans-
port to the cell surface or its incorporation into the viral
envelope [21]. In line with these reports, VSV*DG(EBOV-
GPF88A) and VSV*DG(EBOV-GPP537R) did not replicate on
Vero cells but could be propagated on helper cells express-
ing VSV-G protein. In the absence of VSV-G protein
expression, VSV*DG(EBOV-GPP537R) and VSV*DG(EBOV-
GPF88A) propagated on BHK-G43 cells to low titres suggest-
ing that infectivity of these mutant viruses is significantly
reduced but not completely abolished. The attenuated phe-
notype was not stably maintained when the mutant viruses
were passaged since both VSV*DG(EBOV-GPF88A) and
VSV*DG(EBOV-GPP537R) rapidly acquired compensating
mutations that led to higher infectious virus titres. This
finding underscores the extraordinary plasticity of RNA
viruses. It may be speculated that the VSV/EBOV-GP vac-
cine that was employed in the Geneva clinical phase study
[12, 30] may have undergone mutational changes as well, in
particular when volunteers received a high vaccine dose.
Any mutation that may have allowed higher virus replica-
tion rates could have been responsible for enhanced virus
dissemination, leading to the observed adverse effects.
Unfortunately, VSV/EBOV-GP has not been isolated from
volunteers post vaccination and therefore corresponding
cDNA sequences are not available.
Immunization of guinea pigs with VSV*DG(EBOV-GPF88A)
triggered the production of neutralizing antibodies at levels
that were as high as those induced by immunization with
the propagation-competent VSV*DG-EBOV-GP vaccine. In
contrast, VSV*DG(EBOV-GPP537R) induced lower titres of
neutralizing antibodies suggesting that the P537R mutation
had a negative effect on the immunogenicity of the antigen.
Thus, VSV*DG(EBOV-GPF88A) may be selected for further
vaccine development. First, it will be necessary to introduce
additional mutations into the GP gene that interfere with
virus entry in order to make emergence of revertant viruses
more unlikely and the vaccine candidate genetically more
stable.
In conclusion, propagation-restricted VSV vectors may
represent a safe alternative to propagation-competent VSV
vectors. In a preventative vaccination scenario, propaga-
tion-restricted VSV vectors might be preferentially used in
heterologous prime-boost protocols in combination with
MVA- or adenovirus-vectored EBOV vaccines [42–44].
Finally, propagation-restricted VSV vectors may be used for
the development of safe vector vaccines for protection
against other zoonotic pathogens.
METHODS
Cells
Vero cells (C1008) were purchased from the American
Type Culture Collection (ATCC; Manassas, VA, USA) and
maintained in Glasgow’s minimal essential medium
(GMEM; Life Technologies) supplemented with 5% fetal
bovine serum (FBS). BHK-G43, a transgenic BHK-21 cell
clone expressing the VSV-G protein in a regulated manner
[37], was maintained in GMEM containing 5% FBS. HeLa
(ATCC) and normal human dermal fibroblasts (NHDF;
Lonza, Basel, Switzerland) were maintained in Eagle’s mini-
mal essential medium (EMEM) supplemented with 10%
FBS. The UMNSAH/DF-1 (DF-1) chicken fibroblast cell
line (ATCC) was maintained in Dulbecco’s modified Eagle’s
medium and 10% FBS. All cell lines were cultured at 37

C
in a humidified atmosphere containing 5% CO2, except
DF-1 cells which were kept at 39

C.
Virus
Recombinant VSV* expressing GFP from an extra tran-
scription unit and VSV*Mq expressing a mutant M protein
with four distinct point mutations (Mq) have been
described previously [18]. Propagation-incompetent
VSV*DG(Luc) lacking the G gene and expressing both GFP
and firefly luciferase (Luc) was produced and propagated as
previously described [24]. The recombinant viruses
VSV*MqDG(EBOV-GP), MVA-BN-EBOV-GP and MVA-
BN-EBOV-VLP have recently been described [26]. Recom-
binant MVA-T7 expressing the T7 RNA polymerase was
kindly provided by Gerd Sutter (LMU München, Germany).
Recombinant MVA-BN-EBOV-GP and MVA-BN-EBOV-
VLP were propagated on primary chicken embryo fibro-
blasts and MVA-T7 on DF-1 cells.
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Generation of recombinant plasmids
All plasmids were based on the previously published plasmid
pVSV*DG(HA) encoding a modified VSV (serotype
Indiana) genome with six transcription units [45]. The
fourth transcription unit of this plasmid harbored the influ-
enza virus HA gene (flanked by endonuclease restriction sites
MluI and BstEII) while the fifth transcription unit contained
the enhanced GFP gene flanked by XhoI and NheI restriction
sites. The genomic plasmid pVSV*DG(EBOV-GP) was gen-
erated by replacing the HA gene with a synthetic codon-opti-
mized EBOV-GP gene (accession number NP_066246)
taking advantage of the MluI and BstEII endonuclease
restriction sites. By taking advantage of the XhoI and NheI
endonuclease restriction sites, the GFP gene in pVSV*DG
(EBOV-GP) was replaced with the sNLuc gene (Promega,
Madison, Wisconsin, USA) resulting in pVSVDG(EBOV-
GP,sNLuc). We employed the same strategy to substitute the
GFP gene of pVSV*DG(EBOV-GP) with the EBOV VP40
gene (strain Mayinga, accession number: AF086833; kindly
provided by Elke Mühlberger, Boston University, MA, USA),
which resulted in the recombinant plasmid pVSVDG
(EBOV-GP,VP40). The plasmid pVSV*MqDG(EBOV-GP)
containing the Mq gene with the mutations M33A, M51R,
V221F and S226R [18] was generated by replacing the XbaI/
MluI region of pVSV*DG(EBOV-GP) with the correspond-
ing fragment from pVSV*Mq [18]. EBOV-GP with either
the point mutation F88A or P537R or the deletion of the
mucin-like domain (amino acids 330–489) were generated
by emplyoing overlapping PCR technology. The mutant
EBOV-GP genes then replaced the wild-type EBOV-GP
gene in pVSV*DG(EBOV-GP), resulting in plasmids
pVSV*DG(EBOV-GPF88A), pVSV*DG(EBOV-GPP537R) and
pVSV*DG(EBOV-GP
Dmuc), respectively. A soluble trimeric
EBOV-GP was generated by fusing the cDNA encoding the
EBOV-GP amino acids 1–643 to the nucleotide sequence
encoding the GCN4-pII trimeric coiled coil domain plus a
stop codon (ATGAAACAGATCGAGGATAAGATCGAG-
GAAATTCTGAGCAAGATCTATCACATTGAAAACGA
AATCGCAAGAATCAAGAAACTGGTGGGGGAAAGA
TGA). The resulting secGP3 gene replaced the EBOV-GP
gene in pVSV*DG(EBOV-GP) resulting in pVSV*DG
(secGP3). The genomic plasmid pVSV*DG(secGP3
Dmuc)
was produced correspondingly using the EBOV-GP
Dmuc
gene as a template for amplification of the insert by PCR.
Generation and titration of recombinant VSV
Recombinant VSV vectors were generated on VSV-G pro-
tein expressing BHK-G43 helper cells as described previ-
ously [24]. The viruses were titrated in duplicate on Vero
cells grown in 96-well microtitre plates. The confluent cell
monolayers were inoculated (40 µl well 1) with 10-fold dilu-
tions of each virus for 90min at 37

C and overlaid with
160 µl well 1 of GMEM containing 2% fetal calf serum and
0.9% methylcellulose (Sigma). At 20 h p.i., the GFP-positive
cell foci were counted using an inverted fluorescence micro-
scope and the infectious virus titre calculated and expressed
as ffu ml 1.
For detection of cells that had been infected with chimeric
VSV lacking the GFP reporter, e.g. VSVDG(EBOV-GP,
VP40) or VSVDG(EBOV-GP,sNLuc), the cells were washed
twice with PBS at 20 h p.i. and fixed with 3% paraformalde-
hyde for 30min at room temperature. Excess paraformalde-
hyde was quenched with 0.1 M glycine in PBS for 5min.
The cells were permeabilized with 0.25% Triton X-100 in
PBS for 5min at room temperature and incubated for
60min at room temperature with a monoclonal antibody
(1 : 40 in PBS) directed to the VSV matrix protein (hybrid-
oma clone 23H12; Kerafast, Boston, USA). The cells were
washed three times with PBS and incubated for 1 h at room
temperature with Alexa Fluor 488-conjugated goat anti-
mouse IgG serum (4 µgml 1, 100 µl well 1). After three
wash steps, infected cells were detected with an inverse fluo-
rescence microscope.
Virus replication kinetics
Multi-step replication of recombinant VSV was analysed
using Vero cells. Confluent cell monolayers seeded the day
before in six-well cell-culture plates were inoculated with
virus at 37

C for 1 h using an m.o.i. of 0.0001 ffu cell 1.
Three wells were infected in parallel with each virus. After
adsorption, the inoculum was removed and the cells were
washed three times with 5ml of GMEM before addition of
2.5ml of GMEM containing 5% FBS. At the indicated
times, aliquots of 250 µl were taken and replaced by the
same volume of fresh medium. The aliquots were stored fro-
zen at  70

C until titration (see above).
Serial passaging of recombinant VSV encoding
mutant EBOV-GP
BHK-21 cells (grown in six-well plates) were infected (m.o.i.
of 1 ffu cell 1) with either VSV*DG(EBOV-GPF88A) or
VSV*DG(EBOV-GPP537R) that have been produced on
BHK-G43 helper cells. Following infection, the cells were
maintained for 24 h in the presence of neutralizing anti-
VSV-G antibody (hybridoma clone I1, ATCC). The cell-cul-
ture supernatants were harvested and stored frozen in
aliquots at  70

C. The viruses were diluted 1 : 2 and subse-
quently passaged for five times on BHK-21, each passage
performed in six parallel wells. Virus titres were determined
for each passage as described above. Total RNA was
extracted from BHK-21 cells that have been infected with
passage 5 viruses that turned out to produce increased infec-
tious titres. The RNA was reversed transcribed with Super-
script III reverse transcriptase (Thermo Fisher Scientific)
and random hexamers for priming. The EBOV-GP cDNA
was amplified by PCR with Phusion Hot Start II DNA Poly-
merase (Thermo Fisher Scientific) and inserted into the
pJet1.2 plasmid (Thermo Fisher Scientific). E. coli were
transformed with the recombinant plasmids and selected on
LB agar plates containing ampicillin. The complete ORF of
the cloned GP isolated from three bacterial colonies were
sequenced using BigDye Terminator v3.1 Cycle Sequencing
Kit (Life Technologies) and an Applied Biosystems 3130
automated Genetic Analyzer (Applied Biosystems).
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Immunization of guinea pigs
Dunkin-Hartley guinea pigs were provided by the animal
breeding facility of the Institute of Virology and Immunol-
ogy (IVI) in Mittelh€ausern, Switzerland. Animals with a
weight of 400 to 500 grams were immunized intramuscu-
larly by injection of 250 µl of GMEM containing 2108
ffuml 1 of recombinant VSV (propagated on BHK-G43
helper cells) or 5108 TCID50 of recombinant MVA into
the femoral muscle of each hind leg. After 4 weeks, 2ml of
blood was collected from each animal under anesthesia by
heart puncture. The animals were immunized a second time
using the same vector vaccine, route and dosage. Four weeks
after the second immunization, the guinea pigs were bled
under anesthesia. Sera were prepared by centrifugation of
coagulated blood and stored in aliquots at  20

C.
Fluorescence-linked immunosorbent assay
Vero cells were grown for 24 h in 96-well microtitre plates
and infected with MVA-BN-EBOV-GP using an m.o.i. of
0.05 ffu cell 1. At 24 h p.i., the cells were fixed with 3%
paraformaldehyde in PBS for 30min at room temperature
and subsequently washed two times with PBS containing
0.1 M glycine and once with PBS. The guinea pig immune
sera were serially diluted in PBS and incubated for 60min at
room temperature with the fixed cells (100 µl well 1). The
cells were washed three times with PBS (250 µl well 1) and
subsequently incubated for 60min at room temperature in
the dark with Alexa Fluor 488-conjugated goat anti-guinea
pig IgG serum (4 µgml 1, 100 µl well 1). Finally, the cells
were washed three times as above and then investigated by
fluorescence microscopy (AxioVert 2, Zeiss, Jena,
Germany). The antibody titre was determined by calculating
the reciprocal value of the highest immune serum dilution
allowing discrimination of infected from non-infected Vero
cells. The titration was performed three times and mean val-
ues and SD were calculated.
Plaque reduction neutralization assay
Serial twofold dilutions of guinea pig immune sera were
incubated in quadruplicates for 1 h at 37

C with 100 ffu of
VSV*MqDG(EBOV-GP), which has been propagated on
Vero cells, and then added to Vero cell monolayers grown
in 96-well cell-culture plates. After an incubation period of
1 h at 37

C, the inoculum was removed and 200 µl of
GMEM containing 2% FBS and 0.8% methyl cellulose
(Sigma-Aldrich; Buchs, Switzerland) were added. Following
an incubation period of 24 h at 37

C, the GFP-positive cell
foci were counted under an AxioVert inverted fluorescence
microscope. The reciprocal serum dilution causing a reduc-
tion of plaque numbers by 80% (PRNT80) was calculated.
Inhibition of virus spread in vitro
Vero cells grown in 96-well tissue culture plates (2104
cells/well) were infected for 1 h at 37

C with 50 µl per well
containing 100 ffu of Vero cell-grown VSV* DG(EBOV-GP,
sNLuc). The cells were washed once with GMEM and incu-
bated 24 h at 37

C with 100 µl well 1 of GMEM containing
5% FBS and serially diluted immune sera. To determine
sNLuc activity, 25 µl of the cell-culture supernatant was
transferred to a black 96-well microtitre plate and 25 µl of
Nano-Glo luciferase substrate (Promega, Madison, Wiscon-
sin, USA) was added to each well. Luminescence was
recorded for 1 s with a Centro LB 960 luminometer (Bert-
hold Technologies, Bad Wildbad, Germany). The reciprocal
immune serum dilution leading to 90% inhibition of sNLuc
activity (relative to virus spreading in the presence of naïve
guinea pig serum) was calculated and expressed as IC90.
IFN bioassay
NHDF were grown in 24-well cell-culture plates and
infected with recombinant VSV (m.o.i. of 3 ffu cell 1). The
cell-culture supernatants were collected 24 h p.i. and any
virus was inactivated by heating the supernatants for 30min
at 55

C [23]. The concentration of secreted type I IFN was
determined by titrating the conditioned medium on HeLa
cells as previously described [24]. The dilution of condi-
tioned medium causing 50% suppression of VSV*DG(Luc)-
driven luciferase expression was calculated and expressed as
inhibitory concentration 50% (IC50).
Flow cytometry
Single-cell suspensions of infected cell monolayers were pre-
pared by scraping and thoroughly suspending the cells in
culture medium. Cells were washed with ice-cold PBS and
stained with a LIVE/DEAD fixable violet dead cell staining
kit according to the manufacturer’s instructions (Thermo
Fisher Scientific, Bonn, Germany) to exclude dead cells dur-
ing analysis. Cells were then suspended in ice-cold PBS con-
taining 2% FCS and either fixed/permeabilized with
Fixation/Permeabilization solution kit (BD Biosciences,
Heidelberg, Germany) or left untreated. Fixed/permeabi-
lized and non-permeabilized cells were stained using a pool
of polyclonal mouse serum (1 : 1000) obtained by immuni-
zation of C57BL/6 mice with MVA-BN-EBOV-GP or
MVA-BN-EBOV-VLP, followed by staining with an allo-
phycocyanin-coupled anti-rabbit secondary antibody
(1 : 1000). Cells were analysed for viability, intracellular GFP
expression as a marker of infection as well as for surface and
cytoplasmic expression of EBOV-GP by flow cytometry
using a LSR II flow cytometer (BD Biosciences, Heidelberg,
Germany) and FlowJo software (Tree Star, Ashland,
OR, USA).
Cell surface biotinylation
Vero cells grown in six-well plates were infected with
recombinant VSV using an m.o.i. of 10 ffu cell 1. At 14 h
p.i., cell surface proteins were labelled at 4

C with sulfo-
NHS-LC-LC-biotin (Life Technologies Europe, Zug,
Switzerland) and precipitated from cell lysates with strep-
tavidin-agarose (Life Technologies Europe) as described
previously [46]. The precipitated cell surface proteins were
run on SDS-PAGE (10%) under reducing conditions and
analysed by Western blot using polyclonal anti-EBOV-GP
serum (1 : 4000) from MVA-BN-EBOV-GP vaccinated
guinea pigs.
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Statistical analysis
Mean values and SD were calculated. Data were analysed by
Student’s t-test and P<0.05 was considered significant.
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